Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?
dc.contributor.author | Holbein, M. E. Blair | en_US |
dc.contributor.author | Berglund, Jelena P. | en_US |
dc.contributor.author | Weatherwax, Kevin | en_US |
dc.contributor.author | Gerber, David E. | en_US |
dc.contributor.author | Adamo, Joan E. | en_US |
dc.date.accessioned | 2015-11-12T21:04:37Z | |
dc.date.available | 2016-12-01T14:33:05Z | en |
dc.date.issued | 2015-10 | en_US |
dc.identifier.citation | Holbein, M. E. Blair; Berglund, Jelena P.; Weatherwax, Kevin; Gerber, David E.; Adamo, Joan E. (2015). "Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?." Clinical and Translational Science 8(5): 526-532. | en_US |
dc.identifier.issn | 1752-8054 | en_US |
dc.identifier.issn | 1752-8062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/115991 | |
dc.description.abstract | PurposeThe Food and Drug Administration Expanded Access (EA) program and “Right‐to‐Try” legislation aim to provide seriously ill patients who have no other comparable treatment options to gain access to investigational drugs and biological agents. Physicians and institutions need to understand these programs to respond to questions and requests for access.MethodsFDA EA programs and state and federal legislative efforts to provide investigational products to patients by circumventing FDA regulations were summarized and compared.ResultsThe FDA EA program includes Single Patient‐Investigational New Drug (SP‐IND), Emergency SP‐IND, Intermediate Sized Population IND, and Treatment IND. Approval rates for all categories exceed 99%. Approval requires FDA and Institutional Review Board (IRB) approval, and cooperation of the pharmaceutical partner is essential. “Right‐to‐Try” legislation bypasses some of these steps, but provides no regulatory or safety oversight.ConclusionThe FDA EA program is a reasonable option for patients for whom all other therapeutic interventions have failed. The SP‐IND not only provides patient access to new drugs, but also maintains a balance between immediacy and necessary patient protection. Rather than circumventing existing FDA regulations through proposed legislation, it seems more judicious to provide the knowledge and means to meet the EA requirements. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Phase I | en_US |
dc.subject.other | trials | en_US |
dc.subject.other | FDA | en_US |
dc.subject.other | new agents | en_US |
dc.title | Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation? | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/115991/1/cts12255.pdf | |
dc.identifier.doi | 10.1111/cts.12255 | en_US |
dc.identifier.source | Clinical and Translational Science | en_US |
dc.identifier.citedreference | Rehm D. Debate over ‘Right‐to‐Try’ Laws. May 27, 2014. WAMU Website. http://thedianerehmshow.org/shows/2014‐05‐27/debate‐over‐right‐try‐laws/transcript. Accessed June 9, 2014. | en_US |
dc.identifier.citedreference | Dennis B, Cha AE. ‘Right to Try’ laws spur debate over dying patients' access to experimental drugs. The Washington Post. May 16, 2014. http://www.washingtonpost.com/national/health‐science/right‐to‐try‐laws‐spur‐debate‐over‐dying‐patients‐access‐to‐experimental‐drugs/2014/05/16/820e08c8‐dcfa‐11e3‐b745‐87d39690c5c0_story.html. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Sanghavi DM. The Pills of Last Resort. New York Times Magazine. October 31, 2013. http://www.nytimes.com/2013/11/03/magazine/how‐dying‐patients‐get‐access‐to‐experimental‐drugs.html. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Colorado House Bill 1281; Terminal Patients Investigational Drugs, Colorado House Bill 1281. 2014. | en_US |
dc.identifier.citedreference | Louisiana House Bill 891; Health/Medical Treatment: Authorizes access to investigational treatments for terminally ill patients. 2014. | en_US |
dc.identifier.citedreference | Misssouri State Legislature, House Bill No. 1685, Section A. Chapter 191, RSMo, Amendment. 191.480.1. 2014. | en_US |
dc.identifier.citedreference | Michigan Public Acts 345, 346 2014. 2014. | en_US |
dc.identifier.citedreference | Arizona Proposition 303; House Concurrent Resolution 2005. Arizona Department of State, Office of the Secretary of State Website. http://www.azsos.gov/election/2014/Info/PubPamphlet/english/prop303.htm. Accessed November 5, 2014. | en_US |
dc.identifier.citedreference | 113th United States of America Congress (2013–2014) H.R.4475 – Compassionate Freedom of Choice Act of 2014. 2014. | en_US |
dc.identifier.citedreference | Expanded access to investigational drugs for treatment use. Final rule. Federal register. 2009; 74 ( 155 ): 40900 – 40945. | en_US |
dc.identifier.citedreference | Policy & Guidance, Informed Consent. Office for Human Research Protections (OHRP) Website. http://www.hhs.gov/ohrp/policy/consent/. Accessed October 30, 2014. | en_US |
dc.identifier.citedreference | Exculpatory Language Draft Guidance. Food and Drug Administration Website. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM271036.pdf. Published August 19, 2014. Accessed November 4, 2014. | en_US |
dc.identifier.citedreference | Silverman E. The FDA Says It's More Compassionate Than You Think. Wall Street Journal. May 5, 2014.; http://blogs.wsj.com/corporate‐intelligence/2014/05/05/the‐fda‐says‐its‐more‐compassionate‐than‐you‐think/. Accessed September 3, 2014. | en_US |
dc.identifier.citedreference | Title 21– Food and Drugs Chapter I; Food and Drug Administration; Subchapter D – Drugs for Human Use; Part 312 Investigational New Drug Application, (2014). | en_US |
dc.identifier.citedreference | What Physicians Need to Know Before Requesting Expanded Access/Compassionate Use for Patients. Food and Drug Administration Website. http://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm416812.htm. Published October 28, 2014. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Expanded Access INDs and Protocols. Food and Drug Administration Website. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/ucm373560.htm. Updated March 25, 2014. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Holbein ME. Understanding FDA regulatory requirements for investigational new drug applications for sponsor‐investigators. J Investig Med. 2009; 57 ( 6 ): 688 – 694. | en_US |
dc.identifier.citedreference | Physician Request for a Single Patient IND for Compassionate or Emergency Use. Food and Drug Administration Website. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm. Updated: October 27, 2014. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Emergency IND Application Timeline. Food and Drug Administration Website. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/UCM343024.pdf. Accessed November 7, 2014. | en_US |
dc.identifier.citedreference | Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use — Qs & As. Food and Drug Administration Website. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf. Published May 2013. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | IND Applications for Clinical Treatment (Expanded Access): Overview. Food and Drug Administration Website. http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/ucm351748.htm. Updated Octover 4, 2014. Accessed November 6, 2014. | en_US |
dc.identifier.citedreference | Catalog of Assets for Translational and Clinical Health Research (CATCHR). CTSA Consortium Coordinating Center (C4) Website. http://www.ctsacentral.org/catchr/portfolio. Accessed September 3, 2014. | en_US |
dc.identifier.citedreference | Physician's Checklist for an IND Application for Emergency Treatment. Food and Drug Administration Website. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/UCM343041.pdf. Accessed November 7, 2014. | en_US |
dc.identifier.citedreference | The Right To Try. The Goldwater Institute Website. http://goldwaterinstitute.org/RightToTry. Updated May 18, 2014. Accessed November 6, 2014. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.